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ABSTRACT
Background Up to two-thirds of patients are either
dependent or dead 3 months after thrombectomy for
acute ischemic stroke (AIS). Loss of cerebral
autoregulation may render patients with AIS vulnerable
to decreases in mean arterial pressure (MAP).
Objective To determine whether a fall in MAP during
intervention under general anesthesia (GA) affects
functional outcome.
Methods This subgroup analysis included patients from
the MR CLEAN trial treated with thrombectomy under
GA. The investigated variables were the difference
between MAP at baseline and average MAP during GA
(ΔMAP) as well as the difference between baseline MAP
and the lowest MAP during GA (ΔLMAP). Their
association with a shift towards better outcome on the
modiﬁed Rankin Scale (mRS) after 90 days was
determined using ordinal logistic regression with
adjustment for prognostic baseline variables.
Results Sixty of the 85 patients treated under GA in
MR CLEAN had sufﬁcient anesthetic information
available for the analysis. A greater ΔMAP was
associated with worse outcome (adjusted common OR
(acOR) 0.95 per point mm Hg, 95% CI 0.92 to 0.99).
An average MAP during GA 10 mm Hg lower than
baseline MAP constituted a 1.67 times lower odds of a
shift towards good outcome on the mRS. For ΔLMAP
this association was not signiﬁcant (acOR 0.97 per
mm Hg, 95% CI 0.94 to 1.00, p=0.09).
Conclusions A decrease in MAP during intervention
under GA compared with baseline is associated with
worse outcome.
Trial registration number NTR1804;
ISRCTN10888758; post-results.
BACKGROUND
Although the efﬁcacy of mechanical thrombectomy
in patients with acute ischemic stroke (AIS) has
been proved in multiple studies,1–7 two out of
three treated patients are functionally dependent or
dead (score on the modiﬁed Rankin Scale (mRS)
>2) at 90 days.3 It is unclear whether the use of
general anesthesia (GA) in thrombectomy for AIS
interacts with treatment effect. A recent
meta-analysis found less favorable outcome in
patients treated under GA.8 In a post hoc analysis
of the Multicenter Randomized Clinical Trial of
Endovascular Treatment for AIS in the Netherlands
(MR CLEAN) cohort the signiﬁcant treatment
effect present in the total study population was also
found in patients treated under local anesthesia, but
not in patients treated under GA.9
Blood pressure levels during intervention could
inﬂuence neurologic outcome in patients treated
under GA. The large vessel occlusion required for
thrombectomy in AIS that causes an AIS might also
cause a loss of cerebral autoregulation.10 As a
result, decreases in mean arterial pressure (MAP)
might reduce cerebral blood ﬂow, with subsequent
further neurological deterioration.
This study aims to assess the association of a
drop in blood pressure during intervention under
GA compared with that at baseline with functional
outcome in the MR CLEAN study.
METHODS
Patients and data
We performed a post hoc analysis of the MR
CLEAN trial. In MR CLEAN, patients were rando-
mized between usual care and usual care with add-
itional IA treatment in those with conﬁrmed
proximal anterior circulation AIS. The inclusion
and exclusion criteria for the MR CLEAN trial
have been reported earlier.11 The decision about
the type of anesthetic management during interven-
tion was left to the discretion of the MR CLEAN
centers and treating physicians. However, the
majority of centers had a ﬁxed protocol during the
trial.9 No speciﬁc recommendations were provided
by the steering committee about blood pressure
management. Only patients treated under GA had
peri-interventional blood pressure measurements
available. Patients treated with endovascular
therapy under GA were included in this subgroup
analysis if their data satisﬁed the following quality
criteria: 1. baseline blood pressure was available;
2. blood pressure data could be read/extracted from
the anesthesia report; 3. the induction anesthetic
was listed in the report, and; 4. one blood pressure
registration had been made every <10 min during
anesthesia (one gap of 15 min was allowed). This
last interval was chosen as the intervals between the
reported blood pressure measurements varied
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greatly between centers: from continuous arterial blood pressure
measurements to measurements every 3, 5, or even 8 min.
Baseline data (eg, National Institute of Health Stroke Scale
(NIHSS) at presentation, time from onset to randomization, and
baseline Alberta Stroke Program Early CT Score (ASPECTS))
were extracted from the MR CLEAN database. The baseline
blood pressure was a single brachial measurement at admission
to the emergency department at the recruiting center. Speciﬁc
data concerning the anesthetic management during the interven-
tion were extracted from the available anesthesiology reports.
All data from the anesthesiology reports were collected from the
start of anesthetic induction until awakening. In cases of pro-
longed anesthesia after the intervention, data collection stopped
at the end of the intervention. Extracted data included the type
of induction and maintenance anesthetic, blood pressure levels
during the intervention, and use of blood pressure elevating
medication (eg, norepinephrine). When both invasive and non-
invasive blood pressure measurement was made, invasive meas-
urement was used for data collection as this continuous measure
could be more readily extracted at the proposed intervals. When
a single systolic or diastolic measurement was missing, the value
directly following the missing value was imputed.
From the systolic and diastolic blood pressure measurements
(SBP and DBP, respectively), the MAP was calculated using the
formula MAP=DBP+1/3(SBP−DBP). As our main measure of
blood pressure decrease, we used ΔMAP: the difference between
baseline MAP and the average of all MAP values collected
during GA at intervals of approximately 10 min. Also, to assess
the signiﬁcance of large, small drops in MAP, ΔLMAP was used:
the difference between MAP at baseline and the single lowest
MAP during GA (ﬁgure 1). To correct for the baseline blood
pressure level, both variables were also analyzed as a percentage
of MAP at baseline. For all patients included in this analysis,
written informed consent from patients or their representatives
was obtained before randomization in the MR CLEAN study.
Statistical analyses
Our primary outcome measure is the score on the mRS at
90 days. This scale ranges from 0 (‘no symptoms’) to 6 (‘dead’).
Ordinal logistic regression is used to assess the association of the
decrease in blood pressure with a shift towards better outcome
on the mRS. The mRS was inversely coded (ie, level 0
corresponds to mRS 6) so that a common OR (cOR) below 1
constitutes a drop in blood pressure that is associated with
worse functional outcome. To adjust for known baseline prog-
nostic variables as deﬁned in the MR CLEAN protocol,11 the
models include age, the baseline score on the NIHSS, history of
atrial ﬁbrillation, history of diabetes mellitus, previous stroke,
presence of an internal carotid artery terminus occlusion, and
time from onset to randomization.
Anesthetic agents are known to induce varying degrees of sys-
temic hypotension .12 Therefore, a univariable linear regression
analysis was performed to see whether the type of anesthetic
(propofol vs others) was associated with ΔMAP. As a longer pro-
cedure duration could yield more hypotensive events, its associ-
ation with ΔMAP was determined in a similar manner. All
statistics were performed with R (R foundation for Statistical
Computing, Vienna, Austria, http://www.r-project.org/; used
packages: Ordinal v2015.6-28, http://CRAN.R-project.org/
package=ordinal/; Foreign v0.8-63, http://CRAN.R-project.org/
package=foreign; Tableone v0.7.3, http://CRAN.R-project.org/
package=tableone; ggplot2 v2.2.0, http://CRAN.R-project.org/
package=ggplot2).
RESULTS
Patients and characteristics
Eighty-ﬁve patients underwent endovascular therapy under GA
in the MR CLEAN trial. Six of those were converted from local
anesthetic management, probably owing to increased movement.
For this study, 15 patients were excluded because of partly or
completely missing anesthesiology reports. Another 10 patients
were excluded because the available data did not meet the
predeﬁned quality criteria. The remaining 60 patients were
treated in nine different hospitals. Their characteristics are listed
in table 1.
Figure 1 Schematic representation of the used blood pressure
variables. The dot top left represents the baseline mean arterial
pressure (MAP). Its level is represented by the upper dashed line. The
line with dots represents the MAP values measured approximately
every 10 min during general anesthesia (GA). Their average value is
represented by the middle dashed line. The lowest dots and the lowest
dashed line represent the lowest MAP value during GA. A represents
the difference between baseline MAP and the average MAP during GA
(ΔMAP). B represents the difference between baseline MAP and the
lowest MAP during GA (ΔLMAP).
Table 1 Patient characteristics
Characteristics Value
Number of patients 60
Age, median (IQR) 66 (54–76)
Time from onset to randomization (min), median (IQR) 204 (156–262)
Sex, male, n (%) 35 (58.3)
Medical history, n (%)*
Atrial fibrillation 22 (36.7)
Diabetes mellitus 7 (11.7)
Hypertension 24 (40.0)
Ischemic stroke 12 (20.0)
Myocardial infarction 7 (11.7)
Occlusion location on admission CTA, n (%)
A2 1 (1.7)
ICA-T 15 (25.0)
M1 39 (65.0)
M2 5 (8.3)
Admission NIHSS, median (IQR) 18 (14–20)
Admission ASPECTS, median (IQR)† 8.0 (7.5–10)
Admission blood pressure values (mm Hg), median (IQR)
SBP 140 (126–155)
DBP 80 (70–90)
MAP 100 (92–110)
*Percentages may add up to more than 100 owing to comorbidity.
†As one patient had an A2 occlusion, ASPECTS is available for 59 patients.
ASPECTS, Alberta Stroke Program Early CT Score; CTA, CT angiography; DBP, diastolic
blood pressure; ICA-T, internal carotid artery terminus; MAP, mean arterial pressure;
NIHSS, National Institute of Health Stroke Scale; SBP, systolic blood pressure.
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Data concerning anesthetic management are summarized in
table 2.
Propofol was used most often to induce anesthesia (n=45,
75%) and sevoﬂurane was the compound most used to maintain
anesthesia (n=40, 66.7%). In four cases midazolam was admi-
nistered as premedication (dose <5 mg) for induction with pro-
pofol (n=3) or propofol and esketamine (n=1), and in one case
as inducing anesthetic (9 mg dose) combined with etomidate.
Blood pressure elevating medication was administered in 54 of
60 (90%) patients, but there was considerable variation in the
type and combination. Thirty-six of the 54 (66.7%) patients
received norepinephrine. The median number of blood pressure
measurements extracted from the anesthetic data was 11 (IQR
8–13) and the median procedure duration (groin puncture to
end of procedure/sheath removal) was 69 min (IQR 47–96, data
available for 59 of 60 patients). For four patients it was unclear
whether the reported blood pressure was invasively or non-
invasively measured, in 11 patients only invasive blood pressure
measurements were available, and in 22 only non-invasive bra-
chial measurements. For 23 patients, both non-invasive and
invasive measurements were recorded during anesthesia,
and measurements were extracted according to our
prespeciﬁed methodology (ie, invasive when available). The
median ΔMAP was 17 mm Hg (IQR 6–28) and ΔLMAP
36 mm Hg (IQR 21–53).
Blood pressure decrease and outcome
For all patients, their score on the mRS at 90 days and their
respective ΔMAP values are summarized in ﬁgure 2. The results
of the ordinal regression analyses are summarized in table 3.
A greater ΔMAP was associated with worse outcome (adjusted
common OR (acOR) 0.95 per point mm Hg decrease, 95% CI
0.92 to 0.99).
This ﬁnding shows that for every 10 mm Hg difference
between baseline MAP and average MAP during GA the odds of
a shift toward better outcome on the mRS are 1.67 times lower.
For the ΔLMAP no statistically signiﬁcant association was found
after the adjustment for baseline prognostic variables (acOR
0.97 per mm Hg, 95% CI 0.94 to 1.00, p=0.09). For the
adjusted analyses, ﬁndings were consistent when the variables
were adjusted for the level of baseline MAP by expressing the
size of the difference as the percentage of baseline MAP. No sig-
niﬁcant association was found between the use of propofol as
an induction (β=−8.49, 95% CI −18.00 to 1.01) or mainten-
ance (β=−4.98, 95% CI −13.85 to 3.90) anesthetic and ΔMAP.
There was also no association between the procedure duration
and ΔMAP (β=0.02, 95% CI −0.09 to 0.13).
DISCUSSION
In this post hoc subgroup analysis in patients who received
mechanical thrombectomy under GA during the MR CLEAN
trial, we found that a decrease in peri-interventional MAP was
associated with a worse functional outcome.
Table 2 Intraprocedural anesthetic data
Anesthetic data Value
Number of patients 60
Inducing Anesthesia, n (%)*
Esketamine 1 (1.7)
Etomidate 8 (13.3)
Midazolam 5 (8.3)
Propofol 45 (75.0)
Thiopental 7 (11.7)
Maintenance anesthetic, n (%)*
None listed 3 (5.0)
Isoflurane 1 (1.7)
Propofol 20 (33.3)
Sevoflurane 40 (66.7)
Type of blood pressure elevating medication administered, n (%)*
Ephedrine 30 (50.0)
Norepinephrine 36 (60.0)
Phenylephrine 30 (50.0)
None 6 (10.0)
Type of analgesic administered, n (%)*
Acetominophen 6 (10.0)
Alfentanil 1 (1.7)
Fentanyl 4 (6.7)
Lidocaine 12 (20.0)
Metamizol 1 (1.7)
Morphine 1 (1.7)
Remifentanil 11 (18.3)
Sufentanil 42 (70.0)
None listed 2 (3.3)
Blood pressure values during GA, mm Hg, median (IQR)
SBP 119 (106–130)
DBP 64 (59–71)
MAP 81 (77–91)
Lowest intraprocedural MAP 60 (55–69)
ΔMAP, median (IQR)
mm Hg 17 (6.0–28)
as % of admission blood pressure 17 (7.8–26)
ΔLMAP, median (IQR)
mm Hg 36 (21–53)
as % of admission blood pressure 39 (23–49)
*Percentages may add up to more than 100 owing to combined administration of
medication.
DBP, diastolic blood pressure; GA, general anesthesia; MAP, mean arterial pressure;
SBP, systolic blood pressure; ΔLMAP, difference between baseline and lowest MAP
during GA; ΔMAP, difference between baseline and average MAP during GA.
Figure 2 The association of the difference between baseline mean
arterial pressure (MAP) and average MAP during GA (ΔMAP) with the
score on the modiﬁed Rankin Scale (mRS) at 90 days. The dots
represent individual patients. The boxes depict the median (black bar)
with the IQR.
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While anesthetic management during IA therapy for AIS and
the role of hemodynamic management therein has been dis-
cussed frequently,8 12–16 few studies have speciﬁcally investi-
gated the association of blood pressure with outcome in this
setting. Our ﬁndings suggest that prolonged episodes of lower
MAP compared with baseline during GA are potentially dele-
terious. Conversely, we found no signiﬁcant association with
outcome of the single largest MAP drop during GA after adjust-
ment. Previous studies examined the occurrence of such single
extreme blood pressure values. One did ﬁnd signiﬁcant associa-
tions with outcome,17 while others could not.18 19 Another
study investigating both patients under conscious sedation and
GA found lower minimum diastolic blood pressures in patients
with worse outcome.20 In a population consisting of both
patients treated under GA and local anesthesia, a lowest systolic
blood pressure of <140 mm Hg was found to be associated
with poor outcome.21 The Society for Neuroscience in
Anesthesiology and Critical Care recommends hemodynamic
management with a systolic blood pressure >140 mm Hg.22
However, in patients with a subarachnoid hemorrhage, who
have a similar loss of autoregulation in the brain, no signiﬁcant
association of hypotension with outcome was observed.23
As shown in our study, the use of a single extreme blood pres-
sure variable (ie, the lowest MAP during GA) could not repro-
duce the same association as found when an averaged value of
the intraprocedural MAP was used. Other studies also illustrate
the dependency of results on the chosen variable.17 20
Therefore, the equivocal ﬁndings in the literature can partly be
attributed to severe heterogeneity between studies in the investi-
gated blood pressure variables.
Patients included in this study presented with a median admis-
sion systolic blood pressure of 140 mm Hg. Therefore, 50% of
included patients had admission blood pressure levels lower
than the minimum level recommended by the Society for
Neuroscience in Anesthesiology and Critical Care.22 Blood pres-
sure levels were higher for patients not treated under GA in MR
CLEAN (mean systolic blood pressure of 149 mm Hg),9 or
patients in the intervention arm of other trials (median systolic
blood pressures of 142–150 mm Hg).2 4 5 However, these
levels are still low in comparison with the ﬁnding that 76% of
patients with AIS presented with a systolic blood pressure of
>140 mm Hg.24 We have no clear explanation for the low sys-
tolic blood pressure observed in this study. However, other base-
line characteristics were very similarly distributed in comparison
with the intervention arm of MR CLEAN.3 Also, the majority
of MR CLEAN centers had a ﬁxed protocol for the type of
anesthetic management used. Blood pressure levels dropped
even further during GA in our study. This can probably be
attributed to a lack of awareness about the optimal anesthetic
management for a treatment that was novel at the time inclusion
in the MR CLEAN trial started.
This is the ﬁrst study to assess the association of the differ-
ence between baseline MAP and average MAP during GA with
continuous mRS. We speciﬁcally chose the MAP instead of the
systolic or diastolic blood pressure as we feel it best approxi-
mates the perfusion pressure in the brain. As discussed above,
the use of average intervention MAP is less prone to be inﬂu-
enced by measurement errors and short MAP ﬂuctuations.
Furthermore, the use of continuous mRS is likely to be more
detailed than a dichotomized outcome variable as it takes the
whole disability scale into account.
The study does have several limitations.
First, as this is a post hoc subgroup analysis, its results should
be interpreted with caution, as the original study was not
powered for these analyses.
Second, the multicenter design of MR CLEAN resulted in
heterogeneous anesthesia data that had to be homogenized to
make it suitable for analysis, as well as a large number of
missing anesthesiology reports. This consequently led to a high
exclusion rate (25 of 85 patients) to satisfy our predeﬁned
quality criteria.
Third, as reported earlier and seen in ﬁgure 2, only a few
patients treated under GA in MR CLEAN were functionally
independent after 3 months.9 Therefore at the lower end of the
mRS spectrum only few blood pressure data are available. This
also prevented us from determining a reliable estimate of a
blood pressure threshold for poor outcome.
Fourth, the baseline blood pressure variable is based on a
single measurement and is therefore more prone to measure-
ment error.
Fifth, as blood pressure levels during GA for most patients
were lower than the currently advised minimum of 140 mm Hg
systolic, it was not possible to examine whether adherence to
this minimum blood pressure level was beneﬁcial.22
Sixth, while the average MAP during intervention is more
precise than a single extreme value, it does not take into
account blood pressure variability.
Seventh, the comparison of baseline non-invasively measured
blood pressure and intraprocedural invasive blood pressure mea-
surements might have reduced the precision of the study. As
shown in a large retrospective study, brachial measurements
underestimate hypertensive blood pressure levels and produce
higher values at the lower end of the spectrum.25 As hyperten-
sion is common in patients presenting with an AIS,24 this dis-
crepancy might result in an underestimation of smaller drops in
blood pressure in patients in whom intraprocedural invasive
blood pressure measurements were extracted. Further, in the
patients in whom both invasive and non-invasive measurements
Table 3 Association of lower blood pressure during general anesthesia compared with baseline with a shift in the direction of better outcome
on the modified Rankin Scale (mRS)
Variables
Likelihood of a shift towards better outcome on mRS
cOR 95% CI p Value acOR 95% CI p Value
ΔMAP, per unit mm Hg 0.96 0.93 to 0.99 0.01 0.95 0.92 to 0.99 0.01
As percentage of baseline MAP 0.96 0.92 to 0.99 0.01 0.95 0.92 to 0.99 0.01
ΔLMAP, per unit mm Hg 0.97 0.95 to 1.00 0.03 0.97 0.94 to 1.00 0.09
As percentage of baseline MAP 0.97 0.94 to 1.00 0.09 0.98 0.95 to 1.02 0.43
acOR, adjusted common OR (adjusted for age, history of diabetes mellitus, atrial fibrillation and previous stroke, presence of ICA-T occlusion, time from onset to randomization and
baseline National Institute of Health Stroke Scale); cOR, common OR; GA, general anesthesia; ICA-T, internal carotid artery terminus; MAP, mean arterial pressure; ΔLMAP, difference
between baseline and lowest MAP during GA; ΔMAP, difference between baseline and average MAP during GA.
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were collected this might have led to imprecise estimation of the
true average MAP.
Eighth, patients in this study were not randomized to GA or
alternative managements. Thus one cannot exclude the presence
of any bias toward worse outcome.
Finally, the small sample size led to the inclusion of more
variables in the regression models than the 10 events per vari-
able that rule of thumb would allow. We deviated from this rule
of thumb to allow for adequate correction for potential con-
founders, as was justiﬁed by Vittinghoff and McCulloch.26
The management of blood pressure is also of great import-
ance for patients not treated under GA. Complex, u-curved rela-
tionships with outcome have been observed in patients with
AIS, 27 28 illustrating the delicate line between hyperperfusion
predisposing to extensive cerebral edema, and hypoperfusion
predisposing to infarct growth. Further, falls in blood pressure
also seem to predispose to worse outcomes in patients undergo-
ing intervention under conscious sedation.29 In this light, one
might even postulate that the lack of difference in outcome
between the GA and conscious sedation groups in the recently
published Sedation versus Intubation for Endovascular Stroke
TreAtment (SIESTA, NCT02126085) trial can partly be
explained by the lack of difference in blood pressure levels
between the trial arms.30
The SIESTA trial was the ﬁrst completed trial investigating
the place of GA in thrombectomy, and we await the results of at
least two more: General Or Local Anesthesia in IA THerapy
(GOLIATH, NCT02317237),31 and Sedation Versus GA for
Endovascular Therapy in Acute Stroke—Impact on Neurological
Outcome (ANSTROKE, NCT01872884). Post hoc analyses of
their prospectively collected blood pressure data would yield
more clarity about the association of blood pressure with
outcome in and outside of a GA setting, and would provide
some necessary guidance to improve outcome for patients with
AIS even further.
CONCLUSION
Decreased MAP during intervention under GA compared with
baseline is associated with worse outcome. However, prospect-
ive and systematically collected data are necessary to conﬁrm
this association.
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